Cormorant Asset Management

This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Total investments 134

Average round size

The average size of a deal this fund participated in

$74M

Portfolio companies 125

Rounds per year 16.75

Lead investments 15

Follow on index

How often the fund supports its portfolio startups at next rounds

0.19

Exits 70

Key employees 2

http://cormorant.com

no twitter

United States, Boston

Areas of investment

Biotechnology
Health Care
Medical
Therapeutics
Pharmaceutical

Summary

The main department of described VC is located in the Boston. The fund was located in North America if to be more exact in United States.

Among the most popular fund investment industries, there are Medical, Life Science. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in some founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Among the various public portfolio startups of the fund, we may underline Audentes Therapeutics, Innovent Biologics, ZAI Lab

The increased amount of exits for fund were in 2018. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. The common things for fund are deals in the range of 50 - 100 millions dollars. When the investment is from Cormorant Asset Management the average startup value is 500 millions - 1 billion dollars. Considering the real fund results, this VC is 2 percentage points less often commits exit comparing to other organizations. This Cormorant Asset Management works on 22 percentage points more the average amount of lead investments comparing to the other organizations. The fund is constantly included in 13-24 investment rounds annually.

We also calculated 2 valuable employees in our database.

The standard case for the fund is to invest in rounds with 6-7 partakers. Despite the Cormorant Asset Management, startups are often financed by ARCH Venture Partners, Third Rock Ventures, New Enterprise Associates. The meaningful sponsors for the fund in investment in the same round are Foresite Capital, Wellington Management, EcoR1 Capital. In the next rounds fund is usually obtained by EcoR1 Capital, Visionnaire Ventures, Senvest Capital.

Related Funds

Funds investing in previous rounds

These funds often invest in the rounds preceeding the rounds of Cormorant Asset Management:

1 ARCH Venture Partners

2 RA Capital Management

3 New Enterprise Associates

Typical Co-investors

Cormorant Asset Management is more likely to invest in rounds together with the following funds:

1 KPMG Capital

2 CCB Trust Co

3 Dongxing Securities

Funds investing in following rounds

These funds have a tendency to invest in the following rounds after Cormorant Asset Management:

1 Clearlake Capital Group

2 Branded Strategic Hospitality

3 TechStyle Fashion Group

Notable deals

Company	Industry	Round	Round Size	Date	Investors	Location
Vigil Neuroscience	Biotechnology	1	$90M	18 Aug 2021	Northpond Ventures Atlas Venture OrbiMed Cormorant Asset Management Deep Track Capital Vida Ventures Surveyor Capital Logos Capital Hatteras Venture Partners Invus Lightstone Ventures Pivotal bioVenture Partners Rock Springs Capital	United States, Cambridge
Prime Medicine	Biotechnology Medical	1	$200M	13 Jul 2021	Cormorant Asset Management Redmile Group Moore Strategic Ventures Arrive Newpath Management T. Rowe Price GV Samsara BioCapital PSP Investments ARCH Venture Partners F-Prime Capital Casdin Capital	United States, Cambridge
Tioga Medical	Health Care Medical Device	1	$30M	07 Jul 2021	Cormorant Asset Management AMED Ventures Shifamed Angels The Capital Partnership	United States, " United States"}
Umoja Biopharma	Biopharma Biotechnology Developer Platform Information Technology	1	$210M	15 Jun 2021	Cormorant Asset Management RTW Investments LLC SVB Leerink Presight Capital CaaS Capital Management SoftBank Investment Advisers Temasek Holdings	United States, Seattle
	Health Care Medical Medical Device Wellness	1	$17M	01 Jun 2021	Cormorant Asset Management The Capital Partnership	United States, " United States"}
	Biotechnology Health Care	n/a		28 May 2021	FutureX Capital Primavera Capital Group PICC Capital Investment Management GP Healthcare Capital GL Ventures Forebright Capital Cormorant Asset Management CICC China Life Healthcare Fund ABC International Proxima Ventures Ltd China Asset Management	China, Yinzhou District
NiKang Therapeutics	Biotechnology Health Care Medical	1	$200M	26 May 2021	Perceptive Advisors Wellington Management Surveyor Capital Samsara BioCapital RTW Investments LLC RA Capital Management PFM Health Sciences Pavilion Capital Octagon Capital Advisors Matrix Partners China Logos Capital Lilly Asia Ventures Janus Henderson Investors Invus HBM Healthcare Investments AG EcoR1 Capital Cormorant Asset Management Casdin Capital BlackRock Ally Bridge Group C-Bridge Capital	United States, Wilmington
BiVACOR	Life Science Manufacturing Medical Device	1	$19M	20 May 2021	Cormorant Asset Management OneVentures	United States, Houston
Numab	Biopharma Biotechnology Health Diagnostics Life Science Medical Therapeutics	1	$109M	19 May 2021	Novo Holdings HBM Healthcare Investments AG HBM Partners Cormorant Asset Management Forbion Capital Partners BVF Partners RTW Investments LLC Octagon Capital Advisors BlackRock	Switzerland, " Switzerland"}

News

ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform

– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.

Garuda Therapeutics Raises $72M in Series A Financing

– Garuda Therapeutics from Cambridge develops off-the-shelf, durable blood stem cell therapies.
– Series A funding of $72m brings company valuation to more than $1b.
– The round was led by Aisling Capital, Northpond Ventures and Orbimed, supported by Cormorant Asset Management, Ridgeback Capital Investments, Monashee Investment Management, Sectoral Asset Management, National Resilience, Inc. (Resilience), Mass General Brigham Ventures, among others.

Read All News